1255936-26-5

Basic information

• Product Name: C₂₃H₂₃BrN₄O₃
• Synonyms: C₂₃H₂₃BrN₄O₃
• CAS NO: 1255936-26-5
• Molecular Weight: 483.365
• Mol File: 1255936-26-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₂₃H₂₃BrN₄O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₃H₂₃BrN₄O₃(1255936-26-5)
• EPA Substance Registry System: C₂₃H₂₃BrN₄O₃(1255936-26-5)

Safety Data

• Hazardous Substances Data: 1255936-26-5(Hazardous Substances Data)

Upstream product

• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 128120-93-4 (S)-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromophenyl)-2-oxoethyl]ester 1-tert-butyl ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 875-74-1 (R)-phenylglycine 
• 1255936-24-3 (S)-5-(4-bromophenyl)-2-(pyrrolidin-2-yl)-1H-imidazole 
• 50890-96-5 (2R)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid 

Relevant articles and documents

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C

The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56